RxDoctor Payments Data

Surendra Patel, MD

Internal Medicine · Fresno, CANPI 1346203973

Payments from drug & device makers

$375in general payments, 2019–2025

Across 10 payments — averaging $37.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$125
  • Novo Nordisk$100
  • Abbott$40
  • Mannkind Corporation$32
  • Pfizer$31
  • Astellas Pharma US Inc$19
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$375100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis1$125
Novo Nordisk1$100
Abbott1$40
Mannkind Corporation2$32
Pfizer2$31
Astellas Pharma US Inc1$19
Circassia Inc.1$17
AbbVie1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$375 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$62,546
Medicare patients
166
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate72$66,950
XareltoRivaroxaban45$31,237
LinzessLinaclotide26$15,004
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen619$14,353
EliquisApixaban17$13,642
Fluticasone Propionate HfaFluticasone Propionate17$10,695
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$9,894
Breo ElliptaFluticasone/Vilanterol16$8,375
Atorvastatin Calcium874$7,050
Levetiracetam93$6,429
Metoprolol Succinate364$5,640
Hydroxychloroquine Sulfate65$4,288
Levothyroxine Sodium384$4,195
Albuterol Sulfate HfaAlbuterol Sulfate117$4,135
Metformin Hcl503$3,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$11$15,00426 claims
PfizerEliquis$31$13,64217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →